Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of HW243040 in Healthy Participants
Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Summary
This is a randomised, double-blind, placebo-controlled clinical trial intended to evaluate the safety, tolerability and pharmacokinetic profiles of HW243040 following single and multiple administrations in healthy study participants.
Official title: A Phase 1, Randomized, Double-Blind, Single-Center, Dose-Escalation, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HW243040 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
98
Start Date
2026-08-10
Completion Date
2027-05-31
Last Updated
2026-07-30
Healthy Volunteers
Yes
Conditions
Interventions
HW243040
HW243040 will be administered orally under fasting or fed conditions.
Placebo
Placebo will be administered orally under fasting or fed conditions.
Locations (1)
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China